Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerability profile of pemvidutide...Read more
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug...Read more
Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM)...Read more
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH...Read more
The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing intranasal protective solutions, announced today that it has submitted a...Read more
NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and Drug Administration (FDA) has provided a...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Madrigal Pharmaceuticals | 46.61 8.56 | $591.02 |
| Regeneron Pharmaceuticals | 19.25 2.57 | $767.96 |
| Eli Lilly | 14.56 1.38 | $1,071.44 |
| Mettler-Toledo | 13.09 0.94 | $1,402.51 |
| Intuitive | 10.58 1.88 | $572.47 |
| United Therapeutics | 10.13 2.00 | $517.13 |
| McKesson | 9.69 1.20 | $820.25 |
| BioMarin Pharmaceutical | 9.20 17.71 | $61.15 |
| Vertex Pharmaceuticals | 8.82 1.97 | $456.20 |
| Insmed | 8.29 4.98 | $174.84 |
| Medpace | 8.15 1.45 | $568.36 |
| argenx | 7.94 0.94 | $854.99 |
| Mirum Pharmaceuticals | 7.46 10.61 | $77.74 |
| Krystal Biotech | 7.43 3.18 | $240.80 |
| Natera | 7.22 3.21 | $231.96 |
| TransMedics | 6.64 5.48 | $127.71 |
| HCA Healthcare | 6.42 1.38 | $472.98 |
| iRhythm Technologies | 5.69 3.38 | $174.17 |
| Company | Volume | Last Trade |
|---|---|---|
| Amicus Therapeutics | 986,075,919 | $14.20 |
| ProPhase Labs | 882,779,272 | $0.13 |
| GeoVax Labs | 241,201,952 | $0.16 |
| Psyence Biomedical | 142,239,580 | $1.00 |
| IN8bio | 120,065,588 | $1.21 |
| Incannex Healthcare | 96,163,689 | $0.44 |
| Recursion | 70,183,479 | $4.31 |
| Pfizer | 58,452,347 | $25.26 |
| Altimmune | 54,601,935 | $3.89 |
| ImmunityBio | 45,159,577 | $2.08 |
| Cue Biopharma | 42,610,219 | $0.27 |
| VYNE Therapeutics | 36,245,376 | $0.57 |
| WORK Medical Technology | 35,061,727 | $0.05 |
| Merck | 34,023,177 | $101.09 |
| Iovance Biotherapeutics | 30,150,506 | $2.48 |
| NovaBay Pharmaceuticals | 30,148,737 | $5.30 |
| Zynex | 28,843,046 | $0.31 |
| Bristol-Myers Squibb | 27,951,538 | $54.19 |
| PacBio | 23,948,777 | $1.84 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
